8HOZ
| |
8HOM
| Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro) in Complex with Ensitrelvir | 分子名称: | 3C-like proteinase nsp5, 6-[(6-chloranyl-2-methyl-indazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[[2,4,5-tris(fluoranyl)phenyl]methyl]-1,3,5-triazine-2,4-dione | 著者 | Lin, M, Liu, X. | 登録日 | 2022-12-10 | 公開日 | 2023-12-13 | 実験手法 | X-RAY DIFFRACTION (1.56 Å) | 主引用文献 | Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro) in Complex with Ensitrelvir To Be Published
|
|
8HOL
| |
8HQG
| |
8HQJ
| |
8HQH
| |
8HQI
| |
8HVK
| Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with PF07321332 | 分子名称: | (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 | 著者 | Zeng, P, Zhang, J, Li, J. | 登録日 | 2022-12-27 | 公開日 | 2023-12-27 | 実験手法 | X-RAY DIFFRACTION (1.63 Å) | 主引用文献 | Crystal structure of SARS-Cov-2 main protease
G15S mutant in complex with PF07321332 To Be Published
|
|
8HVO
| Crystal structure of SARS-Cov-2 main protease V186F mutant in complex with PF07321332 | 分子名称: | (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 | 著者 | Zou, X.F, Zhang, J, Li, J. | 登録日 | 2022-12-27 | 公開日 | 2023-12-27 | 実験手法 | X-RAY DIFFRACTION (1.65 Å) | 主引用文献 | Crystal structure of SARS-Cov-2 main protease
V186F mutant in complex with PF07321332 To Be Published
|
|
8HVM
| Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with PF07321332 | 分子名称: | (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 | 著者 | Wang, J, Zhang, J, Li, J. | 登録日 | 2022-12-27 | 公開日 | 2023-12-27 | 実験手法 | X-RAY DIFFRACTION (1.48 Å) | 主引用文献 | Crystal structure of SARS-Cov-2 main protease
K90R mutant in complex with PF07321332 To Be Published
|
|
8HVN
| Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with PF07321332 | 分子名称: | (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 | 著者 | Li, W.W, Zhang, J, Li, J. | 登録日 | 2022-12-27 | 公開日 | 2023-12-27 | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | 主引用文献 | Crystal structure of SARS-Cov-2 main protease
P132H mutant in complex with PF07321332 To Be Published
|
|
8HVL
| Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with PF07321332 | 分子名称: | (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 | 著者 | Zou, X.F, Zhang, J, Li, J. | 登録日 | 2022-12-27 | 公開日 | 2023-12-27 | 実験手法 | X-RAY DIFFRACTION (1.45 Å) | 主引用文献 | Crystal structure of SARS-Cov-2 main protease
M49I mutant in complex with PF07321332 To Be Published
|
|
8HVU
| |
8HVX
| |
8HVW
| |
8HVY
| |
8HVV
| |
8HQF
| |
8INU
| |
8IGO
| Crystal structure of apo SARS-CoV-2 main protease | 分子名称: | 3C-like proteinase nsp5 | 著者 | Huang, X, Zhou, B, Xu, J, Yang, Z, Zhong, N, Xiong, X. | 登録日 | 2023-02-21 | 公開日 | 2023-04-05 | 最終更新日 | 2024-04-17 | 実験手法 | X-RAY DIFFRACTION (2 Å) | 主引用文献 | Preclinical evaluation of the SARS-CoV-2 M pro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat Microbiol, 9, 2024
|
|
8IGN
| Crystal structure of SARS-CoV-2 main protease in complex with RAY1216 | 分子名称: | (3~{S},3~{a}~{S},6~{a}~{R})-2-[(2~{S})-2-cyclohexyl-2-[2,2,2-tris(fluoranyl)ethanoylamino]ethanoyl]-~{N}-[(2~{S})-4-(cyclopentylamino)-3,4-bis(oxidanylidene)-1-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]butan-2-yl]-3,3~{a},4,5,6,6~{a}-hexahydro-1~{H}-cyclopenta[c]pyrrole-3-carboxamide, 3C-like proteinase nsp5 | 著者 | Huang, X, Zhou, B, Xu, J, Yang, Z, Zhong, N, Xiong, X. | 登録日 | 2023-02-21 | 公開日 | 2023-04-05 | 最終更新日 | 2024-04-17 | 実験手法 | X-RAY DIFFRACTION (2.02 Å) | 主引用文献 | Preclinical evaluation of the SARS-CoV-2 M pro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat Microbiol, 9, 2024
|
|
8F2C
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML3006a | 分子名称: | (1R,2S,5S)-N-[(2S,3R)-4-(azetidin-1-yl)-3-hydroxy-4-oxo-1-(2-oxopyrrolidin-1-yl)butan-2-yl]-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5, CHLORIDE ION | 著者 | Westberg, M, Fernandez, D, Lin, M.Z. | 登録日 | 2022-11-07 | 公開日 | 2023-10-11 | 最終更新日 | 2024-03-20 | 実験手法 | X-RAY DIFFRACTION (1.95 Å) | 主引用文献 | An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med, 16, 2024
|
|
8F02
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a4 | 分子名称: | (1R,2S,5S)-N-{(2S,3R)-4-(3,3-dimethylazetidin-1-yl)-3-hydroxy-4-oxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 | 著者 | Westberg, M, Fernandez, D, Lin, M.Z. | 登録日 | 2022-11-01 | 公開日 | 2023-10-11 | 最終更新日 | 2024-03-20 | 実験手法 | X-RAY DIFFRACTION (2 Å) | 主引用文献 | An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med, 16, 2024
|
|
8EOY
| |
8EZV
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a | 分子名称: | (1R,2S,5S)-N-{(2S,3R)-4-(azetidin-1-yl)-3-hydroxy-4-oxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide, 3C-like proteinase nsp5 | 著者 | Westberg, M, Fernandez, D, Lin, M.Z. | 登録日 | 2022-11-01 | 公開日 | 2023-10-11 | 最終更新日 | 2024-03-20 | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | 主引用文献 | An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med, 16, 2024
|
|